Novartis receives third FDA approval for oral Fabhalta® (iptacopan) - the first and only treatment approved in C3 glomerulopathy (C3G)
Novartis has received FDA approval for oral Fabhalta® (iptacopan) to treat adults with C3 glomerulopathy (C3G), marking the first-ever approved treatment for this condition. The approval is based on the Phase III APPEAR-C3G study, which demonstrated sustained proteinuria reduction at one year with favorable safety.
C3G is an ultra-rare kidney disease typically diagnosed around age 23, with approximately 50% of patients progressing to kidney failure within 10 years. Fabhalta is the only oral alternative complement pathway inhibitor targeting the disease's underlying cause, replacing previous reliance on supportive care and broad immunosuppression.
This marks Fabhalta's third FDA approval, following its December 2023 approval for paroxysmal nocturnal hemoglobinuria (PNH) and August 2024 accelerated approval for IgA nephropathy (IgAN). The drug is also under regulatory review in China and Japan for C3G indication.
Novartis ha ricevuto l'approvazione della FDA per Fabhalta® (iptacopan) per trattare adulti affetti da glomerulopatia C3 (C3G), segnando il primo trattamento mai approvato per questa condizione. L'approvazione si basa sullo studio di Fase III APPEAR-C3G, che ha dimostrato una riduzione sostenuta della proteinuria a un anno con un profilo di sicurezza favorevole.
La C3G è una malattia renale ultra-rara tipicamente diagnosticata intorno ai 23 anni, con circa il 50% dei pazienti che progredisce verso l'insufficienza renale entro 10 anni. Fabhalta è l'unico inibitore orale della via del complemento alternativo che mira alla causa sottostante della malattia, sostituendo la precedente dipendenza da cure di supporto e ampia immunosoppressione.
Questo segna il terzo approvazione della FDA per Fabhalta, dopo l'approvazione di dicembre 2023 per l'emoglobinuria notturna parossistica (PNH) e l'approvazione accelerata di agosto 2024 per la nefropatia da IgA (IgAN). Il farmaco è anche sotto revisione normativa in Cina e Giappone per l'indicazione C3G.
Novartis ha recibido la aprobación de la FDA para Fabhalta® (iptacopan) para tratar a adultos con glomerulopatía C3 (C3G), marcando el primer tratamiento aprobado para esta condición. La aprobación se basa en el estudio de Fase III APPEAR-C3G, que demostró una reducción sostenida de la proteinuria a un año con un perfil de seguridad favorable.
La C3G es una enfermedad renal ultra-rara que se diagnostica típicamente alrededor de los 23 años, con aproximadamente el 50% de los pacientes progresando a insuficiencia renal en un plazo de 10 años. Fabhalta es el único inhibidor oral de la vía del complemento alternativo que se dirige a la causa subyacente de la enfermedad, reemplazando la anterior dependencia de cuidados de soporte y amplia inmunosupresión.
Esto marca la tercera aprobación de la FDA para Fabhalta, después de su aprobación en diciembre de 2023 para la hemoglobinuria nocturna paroxística (PNH) y la aprobación acelerada en agosto de 2024 para la nefropatía por IgA (IgAN). El medicamento también está bajo revisión regulatoria en China y Japón para la indicación de C3G.
노바르티스는 성인 C3 사구체병(C3G) 치료를 위한 경구용 Fabhalta® (iptacopan)에 대해 FDA 승인을 받았으며, 이는 이 질환에 대한 최초의 승인된 치료법입니다. 이 승인은 1년 동안 지속적인 단백뇨 감소를 보여주고 안전성 프로필이 우수한 III상 APPEAR-C3G 연구를 기반으로 합니다.
C3G는 일반적으로 23세경에 진단되는 초희귀 신장 질환으로, 약 50%의 환자가 10년 이내에 신부전으로 진행됩니다. Fabhalta는 질환의 근본 원인을 겨냥한 유일한 경구용 보완 경로 억제제로, 이전의 지지 치료 및 광범위한 면역억제에 대한 의존도를 대체합니다.
이는 Fabhalta의 세 번째 FDA 승인으로, 2023년 12월에 발생성 야간 헤모글로빈뇨(PNH)에 대한 승인과 2024년 8월에 IgA 신병증(IgAN)에 대한 가속 승인에 이어진 것입니다. 이 약물은 C3G 적응증에 대해 중국과 일본에서도 규제 검토 중입니다.
Novartis a reçu l'approbation de la FDA pour Fabhalta® (iptacopan) afin de traiter des adultes atteints de glomérulopathie C3 (C3G), marquant le premier traitement jamais approuvé pour cette condition. L'approbation repose sur l'étude de Phase III APPEAR-C3G, qui a démontré une réduction soutenue de la protéinurie après un an avec un profil de sécurité favorable.
La C3G est une maladie rénale ultra-rare généralement diagnostiquée vers l'âge de 23 ans, avec environ 50 % des patients progressant vers une insuffisance rénale dans les 10 ans. Fabhalta est le seul inhibiteur oral du chemin alternatif du complément ciblant la cause sous-jacente de la maladie, remplaçant la dépendance antérieure aux soins de soutien et à l'immunosuppression large.
Ceci marque la troisième approbation de la FDA pour Fabhalta, après son approbation en décembre 2023 pour l'hémoglobinurie nocturne paroxystique (PNH) et son approbation accélérée en août 2024 pour la néphropathie à IgA (IgAN). Le médicament est également en cours d'examen réglementaire en Chine et au Japon pour l'indication C3G.
Novartis hat die FDA-Zulassung für das orale Fabhalta® (iptacopan) zur Behandlung von Erwachsenen mit C3-Glomerulopathie (C3G) erhalten, was die erste genehmigte Behandlung für diese Erkrankung darstellt. Die Zulassung basiert auf der Phase-III-Studie APPEAR-C3G, die eine nachhaltige Reduktion der Proteinurie nach einem Jahr mit einem günstigen Sicherheitsprofil zeigte.
C3G ist eine ultrarare Nierenerkrankung, die typischerweise im Alter von etwa 23 Jahren diagnostiziert wird, wobei etwa 50 % der Patienten innerhalb von 10 Jahren in eine Niereninsuffizienz übergehen. Fabhalta ist der einzige orale Inhibitor des alternativen Komplementwegs, der auf die zugrunde liegende Ursache der Erkrankung abzielt und die frühere Abhängigkeit von unterstützender Pflege und breiter Immunsuppression ersetzt.
Dies markiert die dritte FDA-Zulassung für Fabhalta, nach der Zulassung im Dezember 2023 für paroxysmale nächtliche Hämoglobinurie (PNH) und der beschleunigten Zulassung im August 2024 für IgA-Nephropathie (IgAN). Das Medikament wird auch in China und Japan für die C3G-Indikation überprüft.
- First-ever FDA approved treatment for C3G, addressing an unmet medical need
- Third FDA approval for Fabhalta, demonstrating strong product expansion
- Demonstrated clinical efficacy with proteinuria reduction as early as 14 days
- Favorable safety profile in clinical trials
- Additional regulatory reviews ongoing in China and Japan, indicating potential market expansion
- Treatment requires REMS program due to risk of serious infections
- IgAN approval is conditional and requires confirmatory evidence
- to adult patients only, excluding pediatric population
Insights
Novartis has secured a significant regulatory victory with the FDA approval of Fabhalta (iptacopan) for C3 glomerulopathy (C3G), marking the first and only approved treatment for this ultra-rare kidney disease. This represents Fabhalta's third FDA approval in just 15 months, following authorizations for paroxysmal nocturnal hemoglobinuria (December 2023) and IgAN (August 2024).
The approval addresses a critical unmet medical need in C3G, a devastating condition typically diagnosed in young adults where approximately 50% progress to kidney failure within 10 years. As the only oral alternative complement pathway inhibitor targeting the underlying disease mechanism, Fabhalta offers a paradigm shift from previous management approaches to supportive care and broad immunosuppression.
This approval strategically bolsters Novartis's growing kidney disease portfolio. Beyond Fabhalta's expanding indications, the company is advancing atrasentan (FDA decision expected H1 2025) and zigakibart (Phase III) for IgAN. The complementary mechanisms of action across these assets establish Novartis as a formidable player in nephrology.
While C3G's ultra-rare status limits the addressable patient population, Fabhalta's demonstrated early efficacy (meaningful proteinuria reduction at 14 days) and oral administration offer compelling advantages for treatment adoption and adherence. The favorable safety profile further strengthens its commercial potential, though the REMS requirement for specific vaccinations due to infection risk warrants monitoring.
- Phase III study showed sustained proteinuria reduction at one year with favorable safety1
- Fabhalta is the only oral alternative complement pathway inhibitor thought to target the underlying cause of C3G1-3
- C3G is an ultra-rare kidney disease typically diagnosed in young adults and often progresses to kidney failure2-4
- Novartis continues to advance multiple kidney disease treatments with high unmet need, compounding capabilities and strengthening unique leadership presence
"C3G is a debilitating disease often affecting young people, impacting many aspects of their physical and emotional health, and our previous treatment options came with significant challenges," said Carla Nester, M.D., M.S.A., F.A.S.N., Professor of Pediatrics-Nephrology at the University of
Fabhalta is the only oral inhibitor of the alternative complement pathway to selectively target what is thought to be the underlying cause of the disease1-3. Before the approval of Fabhalta, patients had to rely on supportive care, broad immunosuppression, and symptom management5-6.
"As someone whose family has suffered from C3G across multiple generations, it is difficult to fully express the physical and emotional challenges of living with this unrelenting disease," said Lindsey Fuller, C3G patient and Co-Leader of C3G Warriors. "To finally have an approved treatment – and one that can be taken orally – is something people with C3G have been waiting for. Today's approval brings new hope for me, my family, and so many others."
C3G is a progressive and ultra-rare kidney disease that, until now, has had no approved treatments2-5. The average age of diagnosis is around 23 years old2. Prognosis is poor, with approximately half of people living with C3G progressing to kidney failure within 10 years of diagnosis, requiring lifelong dialysis and/or kidney transplantation2,7. People living with C3G may experience high levels of fatigue, mobility issues affecting everyday life activities, and mental health symptoms, including depression and anxiety8,9.
Data supporting approval
The pivotal Phase III APPEAR-C3G study evaluated the efficacy and safety of twice-daily oral Fabhalta in adult patients with C3G1,10. The study was comprised of a 6-month randomized, double-blind treatment period with Fabhalta compared to placebo in addition to supportive care, followed by an additional 6-month open-label treatment period where all participants received Fabhalta1,10.
Treatment with Fabhalta resulted in clinically meaningful proteinuria reduction, which was seen as early as 14 days and sustained at 12 months1,10. Similarly, in the open-label period, proteinuria reduction was seen in participants who switched to Fabhalta1,10.
Fabhalta demonstrated a favorable safety profile, with no new safety signals1. In patients with C3G, the most common adverse reactions (≥
Last month, Fabhalta received a positive CHMP Opinion in C3G by the European Medicines Agency (EMA)11. Regulatory reviews for this indication are ongoing in
Transforming care in kidney disease
"We extend our deepest gratitude to the patients and investigators who participated in our clinical trials, without whom this first FDA approval in C3G wouldn't have been possible," said Victor Bultó, President US, Novartis. "With this additional approval for Fabhalta – the second in kidney disease – we will leverage our established capabilities and expertise to bring this innovative treatment to patients in need as we work to help transform care for people living with kidney diseases."
This is the third US approval for Fabhalta and its second within the Novartis kidney disease portfolio since August 2024, when Fabhalta was granted accelerated approval by the FDA for the reduction of proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression. Continued approval for this indication is contingent upon confirmatory evidence1. Fabhalta received its first FDA approval in December 2023 for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH)1. Discovered by Novartis, Fabhalta is also being studied in a broad range of other rare kidney diseases, including atypical hemolytic uremic syndrome (aHUS), immune complex membranoproliferative glomerulonephritis (IC-MPGN) and lupus nephritis (LN). Studies are ongoing to evaluate the safety and efficacy profiles in these investigational indications.
In addition to Fabhalta, Novartis is advancing the late-stage development of two additional IgAN therapies with highly differentiated mechanisms of action: atrasentan, an investigational oral endothelin A receptor antagonist that received FDA filing acceptance in Q2 2024 with a decision anticipated in H1 2025, and zigakibart, an investigational subcutaneously administered anti-APRIL monoclonal antibody that is currently in Phase III development.
About APPEAR-C3G
APPEAR-C3G (NCT04817618) is a Phase III multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of twice-daily oral Fabhalta (200 mg) in patients with native kidney C3G1,12. The study comprises a 6-month double-blind period in which adult patients were randomized 1:1 to receive Fabhalta or placebo on top of supportive care, followed by a 6-month open-label period in which all patients receive Fabhalta (including those who were previously on placebo)1,12. The primary endpoint for the double-blind period was proteinuria reduction from baseline at 6 months for Fabhalta compared to placebo as measured by 24-hour urine protein-creatinine ratio (UPCR)1,12. In addition to the results from adult patients with C3G, enrollment is ongoing in a separate cohort of adolescent patients with C3G12.
About C3 glomerulopathy (C3G)
Each year, approximately 1-2 people per million worldwide are newly diagnosed with C3G, a form of membranoproliferative glomerulonephritis (MPGN)3.
In C3G, overactivation of the alternative complement pathway – part of the immune system – causes deposits of C3 protein to build up in kidney glomeruli, which are a network of blood vessels that filter waste and remove extra fluids from the blood4,13. This triggers inflammation and glomerular damage that results in proteinuria (protein in urine), hematuria (blood in urine) and reduced kidney function4,14.
Indication
FABHALTA is a prescription medicine used to treat adults with a kidney disease called complement 3 glomerulopathy (C3G), to reduce protein in the urine (proteinuria).
It is not known if FABHALTA is safe and effective in children with C3G.
Important Safety Information
FABHALTA is a medicine that affects part of the immune system and may lower one's ability to fight infections. FABHALTA increases the chance of getting serious infections caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae type b. These serious infections may quickly become life-threatening or fatal if not recognized and treated early. Patients must complete or update vaccinations against Streptococcus pneumoniae and Neisseria meningitidis at least 2 weeks before the first dose of FABHALTA. If patients have not completed vaccinations and FABHALTA must be started right away, they should receive the required vaccinations as soon as possible. If patients have not been vaccinated and FABHALTA must be started right away, they should also receive antibiotics to take for as long as their health care provider tells them. If patients have been vaccinated against these bacteria in the past, they might need additional vaccinations before starting FABHALTA. Their health care provider will decide if they need additional vaccinations. Vaccines do not prevent all infections caused by encapsulated bacteria. Patients should call their health care provider or get emergency medical care right away if they have any of these signs and symptoms of a serious infection: fever with or without shivers or chills; fever with chest pain and cough; fever with high heart rate; headache and fever; confusion; clammy skin; fever and rash; fever with breathlessness or fast breathing; headache with nausea or vomiting; headache with stiff neck or stiff back; body aches with flu-like symptoms; or eyes sensitive to light. Health care providers will give their patients a Patient Safety Card about the risk of serious infections. Patients must carry it with them at all times during treatment and for 2 weeks after the last dose of FABHALTA. The risk of serious infections may continue for a few weeks after their last dose of FABHALTA. It is important for patients to show this card to any health care provider who treats them. This will help health care providers diagnose and treat patients quickly.
FABHALTA is only available through a program called the FABHALTA Risk Evaluation and Mitigation Strategy (REMS). Before patients can take FABHALTA, their health care provider must enroll in the FABHALTA REMS program, counsel their patients about the risk of serious infections caused by certain bacteria, give their patients information about the symptoms of serious infections, make sure that their patients are vaccinated against serious infections caused by encapsulated bacteria and that they receive antibiotics if they need to start FABHALTA right away and are not up-to-date on vaccinations, as well as give patients a Patient Safety Card about the risk of serious infections.
Patients should not take FABHALTA if they are allergic to FABHALTA or any of the ingredients in FABHALTA. Patients should not take FABHALTA if they have a serious infection caused by encapsulated bacteria, including Streptococcus pneumoniae, Neisseria meningitidis, or Haemophilus influenzae type b, when starting FABHALTA.
Before taking FABHALTA, patients should tell their health care provider about all their medical conditions, including if they have an infection or fever, have liver problems, are pregnant or plan to become pregnant (it is not known if FABHALTA will harm an unborn baby), or are breastfeeding or plan to breastfeed as it is not known if FABHALTA passes into breast milk. Patients should not breastfeed during treatment and for 5 days after the final dose of FABHALTA.
Patients should tell their health care provider about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking FABHALTA with certain other medicines may affect the way FABHALTA works and may cause side effects. Patients should know the medicines they take and the vaccines they receive. Patients should keep a list of them to show their health care provider and pharmacist when they get a new medicine.
FABHALTA may cause serious side effects, including those mentioned above as well as increased cholesterol and triglyceride (lipid) levels in the blood. Health care providers will do blood tests to check patients' cholesterol and triglycerides during treatment with FABHALTA. Health care providers may start patients on medicine to lower cholesterol if needed.
The most common side effects of FABHALTA in adults include: headache; nasal congestion, runny nose, cough, sneezing, and sore throat (nasopharyngitis); diarrhea; pain in the stomach (abdomen); infections (bacterial and viral); nausea; and rash.
Please see full Prescribing Information, including Boxed WARNING and Medication Guide.
Novartis in kidney disease
Building on a 40-year legacy that began in transplant, Novartis is on a mission to empower breakthroughs and transform care in kidney health, starting with kidney conditions that have significant unmet need. Historically these conditions have had considerably less funding and research, leading to a treatment landscape largely focused on reactive or end-stage disease management, often with significant physical, emotional, and financial burdens. Our pipeline targets the underlying causes of disease, with an aim to protect kidney health and delay or prevent dialysis and/or transplantation. Our goal is to help patients get back to living life on their terms—whether at work, in school, or with loved ones, and by partnering with patients, advocates, clinicians, and policymakers we aim to raise awareness, accelerate diagnosis and get patients the right care, sooner.
Disclaimer
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
About Novartis
Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach nearly 300 million people worldwide.
Reimagine medicine with us: Visit us at https://www.novartis.com and https://www.novartis.us and connect with us on LinkedIn, LinkedIn US, Facebook, X/Twitter, X/Twitter US and Instagram.
References
- FABHALTA prescribing information.
East Hanover, NJ : Novartis Pharmaceuticals Corp; March 2025. - Martín B, Smith RJH. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. C3 Glomerulopathy. GeneReviews® [Internet]. Updated 2018. University of
Washington ,Seattle ; 1993-2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1425/. Accessed February 2025. - Schena FP, Esposito P, Rossini M. A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease. Int J Mol Sci. 2020;21(2):525.
- Caravaca-Fontán F, Lucientes L, Cavero T, Praga M. Update on C3 Glomerulopathy: A Complement-Mediated Disease. Nephron. 2020;144(6):272-280.
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021
- National Kidney Foundation. Treatment for C3G. National Kidney Foundation. Available from: https://www.kidney.org/kidney-topics/treatment-c3g. Accessed February 2025.
- Smith RJH, Appel GB, Blom AM, et al. C3 Glomerulopathy – understanding a rare complement-driven renal disease. Nat Rev Nephrol. 2019;15(3):129-143.
- Feldman DL, Bomback A, Nester C. Voice of the patient: report of externally led patient-focused drug development meeting on Complement 3 Glomerulopathy (C3G). National Kidney Foundation. Published March 26, 2018. Available from: https://www.kidney.org/sites/default/files/C3G_EL-PFDD_VoP-Report_3-29-18.pdf. Accessed February 2025.
- Lafayette R, Sidhu R, Proudfoot C, et al. Quality of life and fatigue burden in individuals living with Complement 3 Glomerulopathy – a real-world study. Nephrol Dial Transplant. 2024;39(Suppl 1).
- Smith RJ, Kavanagh D, Vivarelli M, et al. Efficacy and safety of iptacopan in patients with C3 glomerulopathy: 12-Month results from the Phase 3 APPEAR-C3G study. Presented at American Society of Nephrology (ASN) Kidney Week 2024; October 23-27, 2024;
San Diego , CA. - Novartis. Novartis oral Fabhalta® (iptacopan) receives positive CHMP opinion for the treatment of adults living with C3 glomerulopathy (C3G). Available from: https://www.novartis.com/news/media-releases/novartis-oral-fabhalta-iptacopan-receives-positive-chmp-opinion-treatment-adults-living-c3-glomerulopathy-c3g. Accessed March 2025.
- ClinicalTrials.gov. Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy. (APPEAR-C3G). Available from: https://clinicaltrials.gov/study/NCT04817618. Accessed February 2025.
- Ravindran A, Fervenza FC, Smith RJH, Sethi S. C3 Glomerulopathy Associated with Monoclonal Ig is a Distinct Subtype. Kidney Int. 2018;94(1):178-186.
- Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, et al. C3 Glomerulopathy: Clinicopathologic Features and Predictors of Outcome. Clin J Am Soc Nephrol. 2014;9(1):46-53.
# # #
Novartis Media Relations E-mail: media.relations@novartis.com | |
Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: investor.relations@novartis.com
| |
View original content:https://www.prnewswire.com/news-releases/novartis-receives-third-fda-approval-for-oral-fabhalta-iptacopan--the-first-and-only-treatment-approved-in-c3-glomerulopathy-c3g-302407596.html
SOURCE Novartis Pharmaceuticals Corporation
FAQ
What were the key results of Fabhalta's Phase III APPEAR-C3G trial for C3G treatment?
How many FDA approvals has Novartis (NVS) received for Fabhalta and in which conditions?
What is the progression rate of C3G and who does it typically affect?
What makes Fabhalta unique in treating C3G compared to previous treatments?
